Clover Biotech-B (02197): The Global Vaccine Immunization Alliance has unilaterally terminated the pre-purchase agreement and requested the corresponding refund.

Clover Biotech-B (02197) issued an announcement regarding Clover Biopharmaceutical (Hong Kong) Limited (the company’s full...

Zhitong FinanceMar 23 19:18 ET

Threeleaf Clover Biotech-B (02197.HK) announced that its RSV candidate vaccine SCB-1019 has received IND clinical trial approval from the USA and has initiated a clinical study for repeated administration.

On March 24, 2023, GSOM published an announcement that Clover Biopharmaceuticals-B (02197.HK) has received approval from the USA Food and Drug Administration (FDA) for the clinical application (IND) of its RSV candidate vaccine SCB-1019 (a bivalent RSV PreF - trimeric subunit candidate vaccine without an adjuvant, based on Clover Biopharmaceuticals Trimer-Tag protein trimerization vaccine development platform), and the Phase I clinical trial for evaluating the repeat dosing of this candidate vaccine has completed the initial enrollment of participants. The repeat dosing Phase I clinical trial being conducted in the USA has recruited up to 160 elderly subjects.

Gelonghui FinanceMar 23 19:07 ET

Express News | Clover Biopharmaceuticals - Rejects Gavi Alliance's Claim for $224 Million Repayment

ReutersMar 23 19:04 ET

Express News | Clover Biopharmaceuticals - Announces U.S. Ind Clearance and Initiation of Revaccination Clinical Study for Rsv Vaccine Candidate Scb-1019 by US FDA

ReutersMar 23 19:03 ET

Express News | Clover Biopharmaceuticals - Gavi Terminates Advance Purchase Agreement With Clover HK

ReutersMar 23 19:03 ET

CLOVER BIO-B: POSTPONEMENT OF BOARD MEETING DATE

HKEXMar 23 19:02 ET · Announcements

Sancy Clover Bio-B (02197.HK) will hold a Board of Directors meeting on March 24 to consider and approve the annual performance.

Gelonghui, March 12丨Trifolium Biological-B (02197.HK) announced that the company will hold a Board of Directors meeting on March 24, 2025 (Monday) to consider and approve the annual performance for the year ending December 31, 2024, and its release, as well as to assess the payment of the final dividend.

Gelonghui FinanceMar 12 05:33 ET

The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?

Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.

wallstreetcnFeb 7 20:59 ET

Trifolium Bio-B (02197.HK) granted a total of 6.2045 million restricted share units.

On January 20, Glory Exchange announced that on January 20, 2025, the company granted a total of 6.2045 million restricted stock units to one qualified participant in accordance with the terms of the restricted stock unit plan. The restricted stock unit plan is part of the Group's incentive plan. The Board of Directors believes that granting restricted stock units will (i) reward the recipient for their contributions to the growth and development of the Group and provide incentives to retain them for contributing to the Group's continuous development and long-term Global Strategy goals; and (ii) allow the recipient to hold shares.

Gelonghui FinanceJan 20 06:57 ET

Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.

① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.

cls.cnDec 24, 2024 04:16 ET

The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!

Industry pessimistic expectations may improve.

Gelonghui FinanceDec 8, 2024 23:10 ET

How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.

① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.

cls.cnDec 8, 2024 03:48 ET

Adidas Consortium-B (02197) SCB-1019: The potential best in its class, reshaping the global RSV market landscape

With its unique Trimer-Tag technology platform, Clover Biopharmaceuticals' RSV candidate vaccine SCB-1019 is expected to be a potential best-in-class, reshaping the market landscape of RSV vaccines~

Zhitong FinanceOct 31, 2024 20:45 ET

Hong Kong healthcare stocks receive attention from investors again, with Trifolium Biotech surging nearly 15%.

①What is the impact of medical insurance negotiations on pharmaceutical stocks? ②What are the reasons for the rise of Tri Clover Biopharmaceutical and Yimington Corporation?

cls.cnOct 28, 2024 23:05 ET

Hong Kong Stock Market News | Clover Biopharmaceuticals-B (02197) surged more than 14%, positive results from Phase I study of bivalent RSV vaccine.

Adidas AG (02197) rose over 14%, as of the time of publication, up 14.75% to 0.35 Hong Kong dollars, with a turnover of 0.8356 million Hong Kong dollars.

Zhitong FinanceOct 28, 2024 21:43 ET

Express News | Clover Announces Positive Clinical Data for Rsv Vaccine Candidate Scb-1019 Compared Head-to-Head Versus GSK's Arexvy

ReutersOct 28, 2024 18:30 ET

Adidas Biologics-B (02197.HK) announced positive clinical data from the head-to-head comparison of its bivalent RSV candidate vaccine SCB-1019 with the GSK RSV vaccine AREXVY.

Grain Live 29th October | Clover Biopharmaceuticals-B (02197.HK) announced that in Phase I clinical trial, the divalent RSV PreF trimer subunit candidate vaccine SCB-1019 (developed based on Clover Biopharmaceuticals' unique Trimer-Tag protein trimerization vaccine technology platform) evaluated without the use of adjuvants, obtained more positive immunogenicity and safety data in elderly subjects compared to GSK's RSV vaccine AREXVY using AS01E adjuvant in a head-to-head comparison.

Gelonghui FinanceOct 28, 2024 18:20 ET

CLOVER BIO-B: 2024 Interim Report

HKEXSep 19, 2024 06:39 ET · Announcements

Adidas Group Bio-B (02197) fell by 51.00%, now at 0.206 yuan, hitting a 52-week low.

As of 10:13, TripleLeaf Biology-B (02197) fell by 51.00% from the previous closing price to 0.206 yuan, hitting a 52-week low; with a volume of 0.017 million shares and a turnover of 0.0035 million Hong Kong dollars.

金吾財訊Sep 8, 2024 22:13 ET

Clover Biopharmaceuticals Swings to Loss in H1

MT NewswiresAug 28, 2024 07:30 ET